Matches in Wikidata for { <http://www.wikidata.org/entity/Q98221639> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- Q98221639 description "article scientifique publié en 2020" @default.
- Q98221639 description "artículu científicu espublizáu n'agostu de 2020" @default.
- Q98221639 description "scientific article published on 04 August 2020" @default.
- Q98221639 description "wetenschappelijk artikel" @default.
- Q98221639 description "наукова стаття, опублікована 4 серпня 2020" @default.
- Q98221639 name "Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis" @default.
- Q98221639 name "Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis" @default.
- Q98221639 type Item @default.
- Q98221639 label "Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis" @default.
- Q98221639 label "Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis" @default.
- Q98221639 prefLabel "Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis" @default.
- Q98221639 prefLabel "Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis" @default.
- Q98221639 P1433 Q98221639-552B4561-71F1-4AF2-9BDF-6D6D613A3349 @default.
- Q98221639 P1476 Q98221639-089D63A4-504C-4D04-BB85-243B225BB665 @default.
- Q98221639 P2093 Q98221639-0F3D4E3C-6809-4D26-8EE6-7113258D9C73 @default.
- Q98221639 P2093 Q98221639-16E02045-9E26-405D-9539-C7ACF9D5E0AE @default.
- Q98221639 P2093 Q98221639-3761A567-D226-4CB2-8555-95ADAE50FFBB @default.
- Q98221639 P2093 Q98221639-65F4591F-0AEC-4224-97FA-0D262B757005 @default.
- Q98221639 P2093 Q98221639-82D59FA7-2717-45C8-9296-C2D836618F0A @default.
- Q98221639 P2093 Q98221639-94229D11-54B1-4126-9ADC-1D1B51EC78F7 @default.
- Q98221639 P2093 Q98221639-97694F83-C35D-4C92-A406-45856C3E9087 @default.
- Q98221639 P2093 Q98221639-BCE77719-BBC6-4D06-A579-A8138C714D5D @default.
- Q98221639 P2093 Q98221639-C12F0816-D6C9-4957-8650-9A51DF7553CD @default.
- Q98221639 P2093 Q98221639-DD4DB00C-B2E1-4ECF-821E-E369ED459F78 @default.
- Q98221639 P2093 Q98221639-E4EBA775-DD0D-4FE3-A463-73901283E593 @default.
- Q98221639 P275 Q98221639-2c4c650a-d694-4ff1-97b0-74dae3d5055b @default.
- Q98221639 P31 Q98221639-88B5BF13-546F-4C86-BF08-D92EFB24DA32 @default.
- Q98221639 P356 Q98221639-34BFE23E-B06E-42CB-84F1-80E01874BC4E @default.
- Q98221639 P433 Q98221639-BACA288E-971C-4A70-BE63-17354C871455 @default.
- Q98221639 P4510 Q98221639-FAA1FE9B-74B7-4851-935C-C005D4C50F51 @default.
- Q98221639 P478 Q98221639-D001B34D-C86F-41E4-913B-B050DDBA7990 @default.
- Q98221639 P50 Q98221639-1E7AA26B-5F0A-4F2D-86A3-73AD643A789E @default.
- Q98221639 P50 Q98221639-3C874AFA-9502-488B-921C-8669ADBB37F9 @default.
- Q98221639 P50 Q98221639-556E9476-EF1B-4A22-BEE7-802E11DA1077 @default.
- Q98221639 P50 Q98221639-5BDDD9DC-41C0-4F06-8DC3-7899D93D4EE6 @default.
- Q98221639 P50 Q98221639-877B4203-9831-43C0-AAFD-D2EA66EA0A30 @default.
- Q98221639 P50 Q98221639-B2A4B1B5-6B3B-413A-A831-E04B86DD6F57 @default.
- Q98221639 P50 Q98221639-CBE36D98-7363-4736-82C1-393126B89D9E @default.
- Q98221639 P577 Q98221639-37965DB8-85F7-4688-BEC0-404FBFB748D4 @default.
- Q98221639 P6216 Q98221639-381c75ae-eceb-4786-873f-90dd7566b4d0 @default.
- Q98221639 P698 Q98221639-8976EBA8-2EDC-46D3-ACE7-3BAD8DE77C9B @default.
- Q98221639 P932 Q98221639-E36EC7D2-C2DB-46A0-8FE2-62A7611C7493 @default.
- Q98221639 P356 IJMS21155589 @default.
- Q98221639 P698 32759852 @default.
- Q98221639 P1433 Q3153277 @default.
- Q98221639 P1476 "Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis" @default.
- Q98221639 P2093 "Hiroaki Takaya" @default.
- Q98221639 P2093 "Hitoshi Yoshiji" @default.
- Q98221639 P2093 "Kei Moriya" @default.
- Q98221639 P2093 "Koh Kitagawa" @default.
- Q98221639 P2093 "Kosuke Kaji" @default.
- Q98221639 P2093 "Masanori Furukawa" @default.
- Q98221639 P2093 "Naotaka Shimozato" @default.
- Q98221639 P2093 "Norihisa Nishimura" @default.
- Q98221639 P2093 "Takahiro Ozutsumi" @default.
- Q98221639 P2093 "Yasuhiko Sawada" @default.
- Q98221639 P2093 "Yuki Tsuji" @default.
- Q98221639 P275 Q20007257 @default.
- Q98221639 P31 Q13442814 @default.
- Q98221639 P356 "10.3390/IJMS21155589" @default.
- Q98221639 P433 "15" @default.
- Q98221639 P4510 Q1659584 @default.
- Q98221639 P478 "21" @default.
- Q98221639 P50 Q89918003 @default.
- Q98221639 P50 Q90334648 @default.
- Q98221639 P50 Q90871801 @default.
- Q98221639 P50 Q91548878 @default.
- Q98221639 P50 Q95303788 @default.
- Q98221639 P50 Q98221634 @default.
- Q98221639 P50 Q98221636 @default.
- Q98221639 P577 "2020-08-04T00:00:00Z" @default.
- Q98221639 P6216 Q50423863 @default.
- Q98221639 P698 "32759852" @default.
- Q98221639 P932 "7432739" @default.